- Home
- CURV vs DRUG Comparison
CURV vs DRUG Comparison
Compare CURV & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURV
- DRUG
- Stock Information
- Founded
- CURV 2001
- DRUG 2019
- Country
- CURV United States
- DRUG United States
- Employees
- CURV N/A
- DRUG N/A
- Industry
- CURV Clothing/Shoe/Accessory Stores
- DRUG Pharmaceuticals and Biotechnology
- Sector
- CURV Consumer Discretionary
- DRUG Health Care
- Exchange
- CURV Nasdaq
- DRUG Nasdaq
- Market Cap
- CURV 248.6M
- DRUG 199.7M
- IPO Year
- CURV 2021
- DRUG N/A
- Fundamental
- Price
- CURV $2.28
- DRUG $43.96
- Analyst Decision
- CURV Hold
- DRUG Strong Buy
- Analyst Count
- CURV 4
- DRUG 8
- Target Price
- CURV $5.00
- DRUG $83.60
- AVG Volume (30 Days)
- CURV 551.3K
- DRUG 53.0K
- Earning Date
- CURV 09-04-2025
- DRUG 08-11-2025
- Dividend Yield
- CURV N/A
- DRUG N/A
- EPS Growth
- CURV N/A
- DRUG N/A
- EPS
- CURV 0.09
- DRUG N/A
- Revenue
- CURV $1,089,931,000.00
- DRUG N/A
- Revenue This Year
- CURV N/A
- DRUG N/A
- Revenue Next Year
- CURV N/A
- DRUG N/A
- P/E Ratio
- CURV $25.19
- DRUG N/A
- Revenue Growth
- CURV N/A
- DRUG N/A
- 52 Week Low
- CURV $2.08
- DRUG $0.94
- 52 Week High
- CURV $7.25
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- CURV 35.57
- DRUG 69.20
- Support Level
- CURV $2.16
- DRUG $34.19
- Resistance Level
- CURV $2.35
- DRUG $46.13
- Average True Range (ATR)
- CURV 0.14
- DRUG 3.38
- MACD
- CURV 0.06
- DRUG 0.26
- Stochastic Oscillator
- CURV 36.79
- DRUG 82.17
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.